ABTD
REGN icon

Arvest Bank Trust Division’s Regeneron Pharmaceuticals REGN Stock Holding History

Arvest Bank Trust Division’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$377K Buy
+488
New +$374K 0.02% 172

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Arvest Bank Trust Division's REGN Position: Q1 2026 in Review

Arvest Bank Trust Division opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 488 shares worth $377K. The stake represents 0.02% of the portfolio and ranks #172 among its holdings.

1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Arvest Bank Trust Division held 488 shares of Regeneron Pharmaceuticals worth $377K as of Q1 2026.
  • Regeneron Pharmaceuticals was a new Arvest Bank Trust Division position in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.02% of Arvest Bank Trust Division's portfolio in Q1 2026, its #172 holding.
  • 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Arvest Bank Trust Division's 13F filing for Q1 2026, filed 13 May 2026.